Company profile
HAYA Therapeutics
Programmable Therapeutics for Causal Biology - Science Guides Us. The Genome Powers Us. Patients Ground Us.
- Industry
- Biotechnology Research
- Employees
- 68
- Headquarters
- Lausanne - Switzerland / San Diego - USA
- Founded
- 2019
- Office locations
- 2
HAYA Therapeutics company summary
HAYA Therapeutics is a company in the Biotechnology Research industry, headquartered in Lausanne - Switzerland / San Diego - USA, founded in 2019. On LinkedIn the company has around 68 employees. The company lists 2 office locations. Its listed specialties include lncRNA, genomic medicines, fibrosis, Causal Biology, Programmable Therapeutics.
What technology does HAYA Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About HAYA Therapeutics
HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at Lilly Gateway Labs, powered by Alexandria, in San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.
Specialties
Where is HAYA Therapeutics located?
HAYA Therapeutics lists 2 office locations.
Compare companies similar to HAYA Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
HAYA Therapeutics hayatx.com | Biotechnology Research | 68 | 2019 | Lausanne - Switzerland / San Diego - USA |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about HAYA Therapeutics
What does HAYA Therapeutics do?
HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at Lilly Gateway Labs, powered by Alexandria, in San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.
How many employees does HAYA Therapeutics have?
HAYA Therapeutics has around 68 employees on LinkedIn.
Where is HAYA Therapeutics headquartered?
HAYA Therapeutics is headquartered in Lausanne - Switzerland / San Diego - USA.
Where does HAYA Therapeutics have offices?
HAYA Therapeutics lists 2 office locations, including Lausanne - Switzerland / San Diego - USA, CH, CH; San Diego, California, US.
When was HAYA Therapeutics founded?
HAYA Therapeutics was founded in 2019.
Build a lead list from companies like HAYA Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.